We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Safety Concerns Prompt FDA Halt of Celgene’s Revlimid Trial
Safety Concerns Prompt FDA Halt of Celgene’s Revlimid Trial
July 19, 2013
Citing “significant” safety concerns, the FDA has halted a Phase III trial of Celgene’s Revlimid evaluating the drug’s safety and efficacy versus chlorambucil as an initial therapy for chronic lymphocytic leukemia (CLL) in patients 65 years and older.